Lusutrombopag Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 3 mg

Reference Brands: Mulpleta (USA), Mulpleo (EU)

Category: Blood Disorder

Lusutrombopag is an orally administered thrombopoietin receptor agonist used to treat thrombocytopenia (low platelet count) in adults with chronic liver disease who are scheduled for an invasive procedure. It stimulates bone marrow to produce more platelets, helping reduce bleeding risk. Lusutrombopag tablets are typically taken once daily for a short course before the scheduled procedure. The most common side effect reported is headache. It represents a targeted approach to safely elevate platelet counts before medical or dental procedures. Lusutrombopag is available in Tablets and strengths such as 3 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Lusutrombopag is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Lusutrombopag can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Lusutrombopag is a small‑molecule thrombopoietin (TPO) receptor agonist that is used in adult patients with chronic liver disease who have thrombocytopenia (a low number of platelets) and are scheduled to undergo an invasive procedure. It helps stimulate the body’s bone marrow to increase the production of platelets by activating TPO receptors on megakaryocytes and their progenitor cells. This action increases circulating platelet counts, reducing the need for platelet transfusions and lowering the risk of excessive bleeding during or after surgical, dental, or diagnostic procedures. Lusutrombopag is provided in 3 mg oral tablet form, typically administered once daily with or without food for a duration of up to 7 days before the scheduled procedure. Treatment is usually started several days prior to the procedure and the procedure is performed shortly after the final dose. While generally well‑tolerated, common side effects include headache, and rare but serious risks include excessive platelet elevation or thromboembolic events, so monitoring is advised. Lusutrombopag is marketed under brand names such as Mulpleta in the USA and Mulpleo in the EU/UK, and its use has expanded as a non‑transfusion option to elevate platelet counts in high‑risk patients.